Infliximab

Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha and is used to treat autoimmune diseases.

Infliximab

NA

Remicade

NA

NA

NA

It is administered intravenously in a dose of 5 mg/kg on day 1, second week, sixth week, and then after every 6 weeks.

Prescribed for the treatment of psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and Crohn’s disease.

Infliximab can cause jaundice-like reactions, night sweats, fatigue, numbness or tingling, infections, easy bruising, epigastric pain, convulsions, vision changes, unexplained satiety, painful micturition, flushing, myalgia, cough, mild skin rashes, abdominal pain and headache.

Infliximab may interact with vaccines like BCG (Bacille-Calmette Guerin), psoriasis medications including phototherapy, mercaptopurine and azathioprine.

Contraindicated in patients with seizures, immune disorders, multiple sclerosis, diabetes, recent infections, and other heart problems, Guillain-Barre syndrome, COPD or history of cancer.

Store at 20-25°C.

Molecular weight

144190.3 Da

Molecular formula

C6428H9912N1694O1987S46

CAS number

170277-31-3

Precautions

• Increased risk of lymphoma is reported with Infliximab treatment in autoimmune disorder patients.
• Caution should be exercised while travelling to tuberculosis endemic areas.
• Avoid contact with TB patients.